



www.shire.com

Director/PDMR Share Dealings

September 30, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Graham Hetherington was granted on September 27, 2013, under the Shire Sharesave Scheme, an option over 467 ordinary shares at an exercise price of £19.24 per share.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie Deputy Company Secretary

For further information please contact:

Investor Relations

Eric Rojas Sarah Elton-Farr erojas@shire.com seltonfarr@shire.com

+1 781 482 0999 +44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com